Bradykinin potentiates cytokine-induced prostaglandin biosynthesis in osteoblasts by enhanced expression of cyclooxygenase 2, resulting in increased RANKL expression

Arthritis and Rheumatism

Volumn 56, Issue 3, 2007, Pages 910-923

  Brechter, Anna Bernhold ^a   Lerner, Ulf H ^a  

^a UMEÅ UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ARACHIDONIC ACID; BRADYKININ; CYCLOOXYGENASE 2; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1; KININ; KININ B1 RECEPTOR; KININ B2 RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; OSTEOCLAST DIFFERENTIATION FACTOR; PROSTAGLANDIN; RECEPTOR; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; STRESS ACTIVATED PROTEIN KINASE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARACHIDONIC ACID METABOLISM; ARTICLE; CELL LINE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; INFLAMMATION; MOUSE; NONHUMAN; OSTEOBLAST; OSTEOLYSIS; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; PROTEIN FUNCTION;

ANIMALS; BRADYKININ; CELL LINE, TUMOR; CELLS, CULTURED; CYCLOOXYGENASE 2; CYTOKINES; DINOPROSTONE; HUMANS; INTERLEUKIN-1BETA; MICE; MICE, INBRED STRAINS; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; NF-KAPPA B; OSTEOBLASTS; OSTEOPROTEGERIN; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; RECEPTOR, BRADYKININ B1; RECEPTOR, BRADYKININ B2; RNA, MESSENGER; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33947148676     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.22445     Document Type: Article

References (50)

1. Horowitz J, Lorenzo JA. Local regulators of bone: IL-1, TNF, lymphotoxin, interferon-γ, IL-8, IL-10, IL-4, the LIF/IL-6 family, and additional cytokines. In: Bilezikian JP, Raisz LG, Rodan GA, editors. Principles of bone biology. 2nd ed. San Diego: Academic Press; 2002. p. 961-78.
2. Firestein GS. Evolving concepts of rheumatoid arthritis. Nature 2003;423:356-61.
3. Walsh NC, Gravallese EM. Bone loss in inflammatory arthritis: mechanisms and treatment strategies. Curr Opin Rheumatol 2004;16:419-27.
4. Lerner UH. Inflammation-induced bone remodelling in periodontal disease and the influence of post-menopausal osteoporosis. J Dent Res 2006;85:596-607.
5. Worthy K, Figueroa CD, Dieppe PA, Bhoola KD. Kallikreins and kinins: mediators in inflammatory joint disease? Int J Exp Pathol 1990;71:587-601.
6. Montgomery EH, White RR. Kinin generation in the gingival inflammatory response to topically applied bacterial lipopolysaccharides. J Dent Res 1986;65:113-7.
7. Kellermeyer RW, Graham RC Jr. Kinins: possible physiologic and pathologic roles in man. N Engl J Med 1968;279:859-66.
8. Selwyn BM, Figueroa CD, Fink E, Swan A, Dieppe PA, Bhoola KD. A tissue kallikrein in the synovial fluid of patients with rheumatoid arthritis. Ann Rheum Dis 1989;48:128-33.
9. Lerner UH, Jones IL, Gustavsson GT. Bradykinin, a new potential mediator of inflammation-induced bone resorption: studies of the effects on mouse calvarial bones and articular cartilage in vitro. Arthritis Rheum 1987;30:530-40.
10. Lerner UH, Lundberg P. Kinins and neuro-osteogenic factors. In: Bilezikian JP, Raisz LG, Rodan GA, editors. Principles of bone biology. 2nd ed. San Diego: Academic Press; 2002. p. 773-99.
11. Lerner UH. Bradykinin synergistically potentiates interleukin-1 induced bone resorption and prostanoid biosynthesis in neonatal mouse calvarial bones. Biochem Biophys Res Commun 1991;175:775-83.
12. Kakoki M, Kizer CM, Yi X, Takahashi N, Kim H-S, Bagnell CR, et al. Senescence-associated phemotypes in Akita diabetic mice are enhanced by absence of bradykinin B2 receptors. J Clin Invest 2006;116:1302-9.
13. Prado GN, Taylor L, Zhou X, Ricupero D, Mierke DF, Polgar P. Mechanisms regulating the expression, self-maintenance, and signaling-function of the bradykinin B2 and B1 receptors. J Cell Physiol 2002;193:275-86.
14. Leeb-Lundberg LM, Marceau F, Muller-Esterl W, Pettibone DJ, Zuraw BL. International union of pharmacology. XLV. Classification of the kinin receptor family: from molecular mechanisms to pathophysiological consequences. Pharmacol Rev 2005;57:27-77.
15. Fortin J-P, Marceau F. Advances in the development of bradykinin receptor ligands. Curr Top Med Chem 2006;6:1353-63.
16. 1 bradykinin-receptor- mediated prostaglandin formation in osteoblasts and subsequent enhancement of bone resorption. Br J Pharmacol 1990;101:382-6.
17. 2 bradykinin receptors. J Bone Miner Res 1991;6:807-15.
18. Brechter AB, Lerner UH. Characterization of bradykinin receptors in a human osteoblastic cell line. Regul Pept 2002;103:39-51.
19. Lerner UH. Osteoclast formation and resorption. Matrix Biol 2000;19:107-20.
20. Jakobsson P-J, Thoren S, Morgenstern R, Samuelsson B. Identification of human prostaglandin E synthase: a microsomal, glutathione-dependent, inducible enzyme, constituting a potential novel drug target. Proc Natl Acad Sci U S A 1999;96:7220-5.
21. 2 synthase that acts in consert with cyclooxygenase-2. J Biol Chem 2000;275:32783-92.
22. 2 biosynthesis. J Biol Chem 2000;275:32775-83.
23. 2 biosynthesis. J Biochem Mol Biol 2005;38:633-8.
24. Teitelbaum SL, Ross FP. Genetic regulation of osteoclast development and function. Nat Rev Genet 2003;4:638-49.
25. Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature 2003;423:337-42.
26. Lerner UH. New molecules in the tumor necrosis factor ligand and receptor superfamilies with importance for physiological and pathological bone resorption. Crit Rev Oral Biol Med 2004;15:64-81.
27. Gravallese EM, Manning C, Tsay A, Naito A, Pan C, Amento E, et al. Synovial tissue in rheumatoid arthritis is a source of osteoclast differentiation factor. Arthritis Rheum 2000;43:250-8.
28. Shigeyama Y, Pap T, Kunzler P, Simmen BR, Gay RE, Gay S. Expression of osteoclast differentiation factor in rheumatoid arthritis. Arthritis Rheum 2000;43:2523-30.
29. Romas E, Gillespie MT, Martin TJ. Involvement of receptor activator of NFκB ligand and tumor necrosis factor-α in bone destruction in rheumatoid arthritis. Bone 2002;30:340-6.
30. Pettit AR, Ji H, von Stechow D, Muller R, Goldring SR, Choi Y, et al. TRANCE/RANKL knockout mice are protected from bone erosion in a serum transfer model of arthritis. Am J Pathol 2001;159:1689-99.
31. Crotti T, Smith MD, Hirsch R, Soukoulis S, Weedon H, Capone M, et al. Receptor activator of NF κB ligand and osteoprotegerin protein expression in periodontitis. J Periodontal Res 2003;38:380-7.
32. Liu D, Xu JK, Figliomeni L, Huang L, Pavlos NJ, Rogers M, et al. Expression of RANKL and OPG mRNA in periodontal disease: possible involvement in bone destruction. Int J Mol Med 2003;11:17-21.
33. Clover J, Gowen M. Are MG-63 and HOS TE85 human osteosarcoma cell lines representative models of the osteoblastic phenotype? Bone 1994;15:585-91.
34. Ahlen J, Andersson S, Mukohyama H, Roth C, Backman A, Conaway HH, et al. Characterization of the bone-resorptive effect of interleukin-11 in cultured mouse calvarial bones. Bone 2002;31:242-51.
35. Swanson C, Lorentzon M, Conaway HH, Lerner UH. Glucocorticoid regulation of osteoclast differentiation and expression of receptor activator of nuclear factor-κB (NF-κB) ligand, osteoprotegerin, and receptor activator of NF-κB in mouse calvarial bones. Endocrinology 2006;147:3613-22.
36. Lerner UH, Ljunggren O, Dewhirst FE, Boraschi D. Comparison of human interleukin-1β and its 163-171 peptide in bone resorption and the immune response. Cytokine 1991;3:141-8.
37. Palmqvist P, Persson E, Conaway HH, Lerner UH. IL-6, leukemia inhibitory factor, and oncostatin M stimulate bone resorption and regulate the expression of receptor activator of NF-κB ligand, osteoprotegerin, and receptor activator of NF-κB in mouse calvariae. J Immunol 2002;169:3353-62.
38. 2, E-prostanoid 2 (EP2), and EP4 receptors. J Biol Chem 2003;278:49954-64.
39. 2 on interleukin-1β-induced cyclooxygenase-2 expression in human airway smooth-muscle cells. Am J Respir Crit Care Med 2000;162:2272-7.
40. Chen BC, Chung CC, Lei HC, Chang MS, Hsu MJ, Huang CL, et al. Bradykinin B2 receptor mediates NF-κB activation and cyclooxygenase-2 expression via the Ras/Raf-1/ERK pathway in human airway epithelial cells. J Immunol 2004;173:5219-28.
41. Nie M, Pang L, Inoue H, Knox A. Transcriptional regulation of cyclooxygenase-2 by bradykinin and interleukin-1β in human airway smooth muscle cells: involvement of different promotor elements, transcription factors, and histone H4 acetylation. Mol Cell Biol 2003;23:9233-44.
42. Thoren S, Weinander R, Saha S, Jegerschold C, Pettersson PL, Samuelsson B, et al. Human microsomal prostaglandin E synthase-1: purification, functional characterization, and projection structure determination. J Biol Chem 2003;278:22199-209.
43. Kondo A, Togari A. Activation of osteoblastic functions by a mediator of pain, bradykinin. Biochem Pharmacol 2004;68:1423-31.
44. 2+ in the osteoblastic cell line MC3T3-E1. J Bone Miner Res 1991;6:443-52.
45. Phagoo SB, Reddi K, Anderson KD, Leeb-Lundberg LM, Warburton D. Bradykinin B1 receptor up-regulation by interleukin-1β and B1 agonist occurs through independent and synergistic intracellular signaling mechanisms in human lung fibroblasts. J Pharmacol Expr Ther 2001;298:77-85.
46. Gravallese EM. Bone destruction in arthritis. Ann Rheum Dis 2002;61:84-6.
47. Vidal ON, Sjogren K, Eriksson BI, Ljunggren O, Ohlsson C. Osteoprotegerin mRNA is increased by interleukin-1α in the human osteosarcoma cell line MG-63 and in human osteoblast-like cells. Biochem Biophys Res Commun 1998;248:696-700.
48. Hofbauer LC, Lacey DL, Dunstan CR, Spelsberg TC, Riggs BL, Khosla S. Interleukin-1β and tumor necrosis factor-α, but not interleukin-6, stimulate osteoprotegerin ligand gene expression in human osteoblastic cells. Bone 1999;25:255-9.
49. Brandstrom H, Bjorkman T, Ljunggren O. Regulation of osteoprotegerin secretion from primary cultures of human bone marrow stromal cells. Biochem Biophys Res Commun 2001;280:831-5.
50. Pantouli E, Boehm MM, Koka S. Inflammatory cytokines activate p38 MAPK to induce osteoprotegerin synthesis in MG-63 cells. Biochem Biophys Res Commun 2005;329:224-9.